



**MARKET SNAPSHOT**

|                         |               |
|-------------------------|---------------|
| Stock price (5/13/16)   | \$1.23        |
| 52-week range           | \$1.92-\$0.68 |
| Market capitalization   | ~\$52M        |
| Shares outstanding      | 43M           |
| Institutional ownership | NA            |
| Fiscal year-end         | Dec. 31       |

CASI Pharmaceuticals Inc. (NASDAQ: CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs. CASI's mission is to become an integrated biopharmaceutical company with major market share in China, while establishing partnerships for global development and commercialization. Our pipeline includes ENMD-2076, a proprietary orally-active, Aurora A/angiogenic kinase inhibitor, currently in multiple Phase 2 oncology studies, greater China regional rights to MARQIBO®, EVOMELA™, ZEVALIN®, and 2ME2 (2-methoxyestradiol), an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties, as well as two preclinical stage oncology drug candidates.

**COMPELLING PIPELINE**

**CLINICAL CANDIDATE**

|                  | INDICATION                           | PRE-CLINICAL   | IND/CTA | PHASE 1 | PHASE 2 | PHASE 3 |
|------------------|--------------------------------------|----------------|---------|---------|---------|---------|
| <b>ENMD-2076</b> | <b>Triple-Negative Breast Cancer</b> |                |         |         |         |         |
|                  | U.S. sites                           | [Progress bar] |         |         |         |         |
|                  | China sites                          | [Progress bar] |         |         |         |         |
|                  | <b>Soft-Tissue Sarcoma</b>           |                |         |         |         |         |
|                  | Canada sites                         | [Progress bar] |         |         |         |         |
|                  | China sites                          | [Progress bar] |         |         |         |         |
|                  | <b>Ovarian Clear Cell Carcinoma</b>  |                |         |         |         |         |
|                  | Canada site                          | [Progress bar] |         |         |         |         |
|                  | China sites                          | [Progress bar] |         |         |         |         |
|                  | <b>Fibrolamellar Carcinoma</b>       |                |         |         |         |         |
| U.S. sites       | [Progress bar]                       |                |         |         |         |         |
| China sites      | [Progress bar]                       |                |         |         |         |         |

**PRE-CLINICAL DRUG CANDIDATES**

|                  | INDICATION           | PRE-CLINICAL   | IND/CTA | PHASE 1 | PHASE 2 | PHASE 3 |
|------------------|----------------------|----------------|---------|---------|---------|---------|
| <b>CASI-2ME2</b> | Autoimmune disorders | [Progress bar] |         |         |         |         |
| <b>CASI-001</b>  | Oncology             | [Progress bar] |         |         |         |         |
| <b>CASI-002</b>  | Oncology             | [Progress bar] |         |         |         |         |

**LATE-STAGE DRUG CANDIDATES FOR CHINA REGION ONLY**

|                 | INDICATION (FDA APPROVED)    | IN-LICENSED FROM SPECTRUM | CTA FILING & REVIEW | CONFIRMATORY TRIAL | NDA FILING & REVIEW | LAUNCH IN CHINA |
|-----------------|------------------------------|---------------------------|---------------------|--------------------|---------------------|-----------------|
| <b>MARQIBO®</b> | Acute Lymphoblastic Leukemia | [Progress bar]            |                     |                    |                     |                 |
| <b>EVOMELA™</b> | Multiple Myeloma             | [Progress bar]            |                     |                    |                     |                 |
| <b>ZEVALIN®</b> | Non-Hodgkin's Lymphoma       | [Progress bar]            |                     |                    |                     |                 |

**2016-2017 MILESTONES**

- ✓ File import drug application for MARQIBO with China FDA
- ✓ Complete patient enrollment for Stage 1 of fibrolamellar Phase 2 trials in the U.S.
- Poster at ASCO on ENMD-2076 Phase 2 trials in ovarian clear cell carcinoma
- File import drug application for EVOMELA with China FDA
- Clinical update on ENMD-2076 in ovarian clear cell carcinoma
- Clinical update on ENMD-2076 from Stage 1 of fibrolamellar carcinoma Phase 2 trials in the U.S.
- File for EMA orphan drug designation for ENMD-2076 in ovarian cancer
- File import drug application for ZEVALIN with China FDA
- Complete patient enrollment of U.S. triple-negative breast cancer Phase 2 trial
- Complete patient enrollment of China triple-negative breast cancer Phase 2 trial
- Complete correlative biomarker analysis for patient populations likely to benefit from ENMD-2076 from ovarian clear cell carcinoma, triple-negative breast cancer, and/or soft tissue sarcoma trials
- Advance ENMD-2076 in selected indication(s) to Phase 2b/Phase 3 trials
- Advance development of CASI-001 for IND filings in China
- Advance development of CASI-002 into IND-enabling studies in China
- Provide clinical update on ENMD-2076 from Phase 2 trials in triple-negative breast cancer
- In-license additional drug candidates for pipeline
- Initiate China confirmatory trial for MARQIBO
- Initiate China confirmatory trial for EVOMELA

## COMPANY HIGHLIGHTS

- **Significant market opportunities.** As a U.S.-based company with a wholly owned subsidiary and R&D operations in China, CASI is well positioned to take advantage of China’s biopharmaceutical market, the world’s fastest-growing and on track to be the world’s second largest by 2017. CASI has a proven ability to navigate the clinical and regulatory pathways in both North America and in China, and is competitively differentiated with other local companies in that region.
- **Compelling business model.** CASI presents a compelling North America/China business model with important synergies for cost-effective drug development and commercialization. These include capabilities of not only having U.S. innovative products acquired, developed, and tapped into China’s market but also having proprietary products identified, acquired and/or developed in China for reaching a global market.
- **Strong Product pipeline.** CASI has exclusive rights to three U.S. FDA-approved oncology drugs, MARQIBO, EVOMELA and ZEVALIN for development and commercialization in greater China, including Taiwan, Hong Kong and Macau. ZEVALIN is now available in Hong Kong. ENMD-2076 is in multiple Phase 2 trials in North America for the treatment of ovarian clear cell carcinoma, triple-negative breast cancer, soft tissue sarcoma and fibrolamellar carcinoma. A Phase 2 trial for TNBC was started in China and is currently recruiting patients. 2ME2 has shown promising preclinical results in autoimmune disorders including rheumatoid arthritis and multiple sclerosis, and has an approved IND in rheumatoid arthritis in the U.S. CASI is also actively pursuing in-licensing or acquisition opportunities for additional drug candidates in North America and China while executing internal evaluation and development of innovative drug candidates in its R&D operations in Beijing.
- **An experienced leadership team with a history of success.** CASI has a seasoned, bi-cultural Board of Directors and executive management team with extensive knowledge and successful track records of developing innovative drugs in North America and China. Led by CEO Ken K. Ren, Ph.D. who has overseen multiple clinical trials, regulatory and development activities in China for multinational companies, is an experienced team in China with success in bringing products from preclinical research to clinical trials, regulatory filings, approvals and product launches.
- **Strong cash position.** CASI has a strong cash position with long term commitment from IDG-ACCEL, the company’s largest shareholder, Kleiner Perkins Caufield Byers China, and partner support from Spectrum Pharmaceuticals, Inc.

## SERVING THE WORLD’S LARGEST AND FASTEST GROWING MARKET

China Spending and Growth, 2008-2017



The Chinese healthcare market is undergoing massive expansion, and universal healthcare coverage is expected to be in place by 2020. China is projected to be the second largest pharmaceutical market in the world with estimated sales of more than \$170 billion by the year 2017. The growth of the Chinese oncology drug market is particularly strong and will likely become the world’s largest in the next 5-10 years. The IMS Institute for Healthcare Informatics expects development of a “much larger high quality, low unit price locally-sourced medicines market, with a compensatory growth in the protected innovative medicines sector, funded by a rise in private health insurance.” CASI is well positioned to benefit from this trend.

CASI Pharmaceuticals, Inc.  
 9620 Medical Center Drive, Ste. 300  
 Rockville, MD 20850  
 Denise Gianetti  
 (240) 864-2600  
 denis.eg@CASIpHarmaceuticals.com  
 www.CASIpHarmaceuticals.com

Beijing Office  
 FullLink Plaza, Suite B1214-1215  
 No. 18 Chaoyangmenwai Street  
 Chaoyang, Beijing 100020 P. R. China

Torrey Hills Capital  
 16236 San Dieguito Road, Suite 2-10  
 P.O. Box 8071  
 Rancho Santa Fe, CA 92067  
 Jim Macdonald  
 858.456.7300  
 jm@sdtHC.com